Currently at AbbVie I am the Director of Therapeutic Areas Strategic Planning and Scientific Initiatives. In this leadership role, I report to and serve as Chief of Staff for the Vice President of Therapeutic Areas, International Development, and Development Excellence. I partner with the therapeutic area heads to drive long‐range strategies across Immunology, Virology, Neurology, and General Medicine. Additionally, I work with multiple functional areas to assess external molecules and I provide strategic input into the development of disease opportunity profiles. I also help identify, prioritize, and nurture external collaborations, as well as coordinate the generation of competitive environment assessments.
In my spare time, I am an award-winning professional photographer doing freelance commercial work, sports, fine art, nature/wildlife, portraits, weddings, and other events. I am a member of the National Press Photographers Association.
As the Director of Portfolio Strategy for Immunology, my role was to optimize the value of AbbVie's broad range of current and future immunology assets, including HUMIRA®, the best-selling pharmaceutical product in the world. I was a core member of the Immunology Therapeutic Area Strategy Council and the HUMIRA® Leadership Board, and I worked closely with the Immunology Vice Presidents to develop long‐range strategic plans for both HUMIRA® and the pipeline. One major accomplishment was leading the transition from a large Therapeutic Executive Committee model to a smaller, more focused Therapeutic Area Strategy Council model for Immunology, the first therapeutic area at AbbVie to make this transition. Another significant achievement was the harmonization of the HUMIRA® and Immunology Pipeline strategies into one long-range plan.
In Drug Development Project Management at AbbVie, I managed global cross-functional teams advancing new molecular entities and marketed products through clinical studies. As Project Manager, I served as the "Chief Operating Officer" of Asset Leadership Boards and Asset Development Teams. My accomplishments included: ● Advanced HUMIRA® from Phase 3 start to global launch for Hidradenitis Suppurativa. ● Advanced HUMIRA® from Phase 3 start to EU regulatory approval for Pediatric Psoriasis. ● Advanced ABT‐494 (small molecule JAK inhibitor) from Preclinical through: - Phases 1 and 2 to a 'go' decision for Phase 3 for Rheumatoid Arthritis, - Phase 2 in Crohn's Disease. ● Advanced ABT‐981 (IL1a/b Dual Variable Domain Immunoglobulin) through Phase 1 in Osteoarthritis. ● Advanced Tregalizumab (CD4 antibody, partnered with Biotest AG) through Phase 2 in Rheumatoid Arthritis. I also served as the project manager of the Immunology Therapeutic Executive Committee and the HUMIRA® Therapeutic Executive Committee. Contributed to nine Disease Opportunity Profiles that were presented to and approved by the Pharmaceutical Executive Committee, chaired by the CEO.
The Center for Pharmaceutical Development (CPD) is a National Science Foundation Industry/University Cooperative Research Center. CPD addresses current challenges in the pharmaceutical industry by providing a forum for academic and industrial scientists to develop novel approaches for the improvement of pharmaceutical API manufacturing, drug product formulation, and analytical methods. I was one of the founding members of the Industrial Advisory Board and I was elected Vice-Chair and then Chair, serving while I worked at Abbott and then AbbVie.
At Abbott I was a lab manager in Drug Product Development. I led groups of research scientists, many at senior/PhD levels and I was the Pharmaceutics lead on many cross-functional project teams. I enabled seven molecules to be advanced from discovery into preclinical development, in the therapeutic areas of oncology, dyslipidemia, pain, and neuroscience. Three of these compounds are still in clinical trials: ● Ilorasertib, Aurora kinase inhibitor for Oncology ● ABT-957, Calpain inhibitor for Alzheimer's Disease ● ABT-436, V1b antagonist for Depression and Alcohol Dependance
At Schering-Plough I was a scientist and supervisor in CMC. My first role was in analytical, in the GMP Physical Characterization and Drug Substance Analysis group. Subsequently I moved into the formulation area, in the Discovery Support and Pharmaceutical Chemistry group. I enabled the advancement of four molecules from discovery into preclinical development (one in oncology, one in COPD, and two anti-tussives), and I contributed to the following marketed products: ● CLARINEX® (desloratadine) - antihistamine ● NOXAFIL® (posaconazole) - anti-fungal ● ZETIA® (ezetimibe) - anti-cholesterol ● ASMANEX®/NASONEX® (mometasone furoate) - glucocorticosteroid
Mini-MBA Certificate and Project Management Certificate
B.A.
Concentration: Physics and Chemistry
Ph.D.
Concentration: Chemistry
Pharmaceuticals, Pharmaceutics, Pharmaceutical Sciences, Drug Development, Drug Discovery, R&D, Chemistry, Oncology, Immunology, Neuroscience, Dermatology, Clinical Development, Project Management, Lean, Six Sigma, Lean Six Sigma, Business Excellence, Formulation, Drug Delivery, Biotechnology, Analytical Chemistry, Cross-Functional Team Leadership, Business Strategy, Tech Transfer, CMC, Management, Team Leadership, Clinical Trials, Regulatory Affairs, Program Management, Drug Product, Biopharmaceuticals, Strategic Planning, Business Intelligence, Marketing Strategy, Leadership Development, Business Process Improvement, Operational Excellence, Mentoring, Continuous Improvement, Staff Development, Mathematics, Physics, Analytical Development, Pharmaceutical Development, Solid-State Chemistry, Green Bay Packers, Boy Scouts of America, Golf, Basketball, Photography, Fishing, Half-Marathons, Marathons, Running
This BrandYourself profile is automatically optimized to show up high in Google
Social Networks